Guardant Health (GH) and Pfizer, (PFE) disclosed a new, multi-year collaboration agreement on Thursday to support development and commercialization of Pfizer's oncology portfolio using the Guardant's Infinity liquid biopsy platform.
Under the terms of the new partnership, the companies will evaluate the clinical use of circulating tumor DNA levels as a surrogate endpoint to monitor therapy response as well as related blood-based epigenomic analysis.
The collaboration also will provide Pfizer with access to Guardant's liquid biopsy tests in China as the companies conduct clinical trials that include Chinese cohorts. Guardant previously formed a strategic partnership with Hong Kong-listed Adicon Holdings to offer Guardant tests to biopharmaceutical companies conducting clinical studies in China.
Guardant shares recently were more than 1% higher in Thursday trading. Pfizer was narrowly higher this morning.
Price: 46.30, Change: +0.66, Percent Change: +1.45
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。